Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
Study First Submitted
Endpoints
Primary
Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Timeframe: During Cycle 1 (cycle length = 21 days)
Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Timeframe: Up to approximately 2.9 years
Phase 2: Objective Response Rate (ORR) as Assessed by Investigator
Timeframe: Up to approximately 2.9 years
Secondary (11)
Phase 1: ORR as Assessed by Investigator
Phase 2: Number of Participants With TEAEs
Phase 1 and 2: Duration of Response (DoR) as Assessed by the Investigator
Phase 1 and 2: Clinical Benefit Rate (CBR) as Assessed by the Investigator
Phase 1 and 2: Disease Control Rate (DCR) as Assessed by the Investigator
Show 6 moreShow less
Phase 1 and 2: Time to Response (TTR) as Assessed by the Investigator
Phase 1 and 2: Best Percentage Change in the SoD of Measurable Tumors as Assessed by Investigator
Phase 1 and 2: Progression-free Survival (PFS) as Assessed by the Investigator
Phase 1 and 2: Overall Survival (OS)
Phase 1 and 2: Plasma Concentration of Dato-DXd, Total Anti-TROP2 Antibody and MAAA-1181a
Phase 1 and 2: Percentage of Participants With Positive Anti-drug Antibodies (ADAs)
Arms and interventions
Sub-study 1: Phase 1: Part 1: Dato-DXd + EVExperimental
Participants will be administered Dato-DXd, intravenously (IV), along with EV, administered IV.
Sub-study 1: Phase 1: Part 2: Dato-DXd + EV + PembrolizumabExperimental
Based on the maximum tolerated dose (MTD) determined by Phase 1 Part 1, participants will be administered Dato-DXd, IV, along with EV and pembrolizumab, administered IV.
Sub-study 1: Phase 2: Group A: Dato-DXd + EV + PembrolizumabExperimental
Participants will be administered Dato-DXd, at recommended Phase 2 dose (RP2D) based on Phase 1 data, along with EV and pembrolizumab, administered IV.
Sub-study 1: Phase 2: Group B: EV + PembrolizumabActive comparator
Participants will be administered EV, IV, along with pembrolizumab, IV.